Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of tralokinumab in atopic dermatitis (Japan)
jRCT2080224092Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of tralokinumab in atopic dermatitis (AD), sponsored by LEO Pharma. Primary endpoint: Long-term safety of tralokinumab. Started Oct 2018; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224092.